Experimental Mouse Model of Bleomycin‐Induced Skin Fibrosis

Systemic sclerosis (SSc) refers to an autoimmune disease, which is manifested by inflammation, vasculopathy, and fibrosis of the skin and internal organs. There are a number of different animal models recapitulating specific aspects of SSc. The experimental mouse model of bleomycin‐induced skin fibrosis is commonly used to study the pathogenesis observed in SSc. In this model, repetitive intradermal injections of the cytotoxic agent bleomycin trigger progressive skin thickening, associated with excessive accumulation of collagen, infiltration of immune cells, and formation of α‐smooth muscle actin (α‐SMA)‐positive myofibroblasts. In this article, we provide a detailed protocol for the induction of skin fibrosis in experimental mice by bleomycin. Moreover, we describe procedures for processing and analyzing affected skin tissue, provide troubleshooting, highlight advantages and limitations of the presented model, and critically discuss representative results. © 2019 by John Wiley & Sons, Inc.

[1]  T. Wynn,et al.  Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis. , 2017, American journal of physiology. Lung cellular and molecular physiology.

[2]  Toshiyuki Yamamoto,et al.  Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin , 2015, Experimental dermatology.

[3]  Y. Allanore,et al.  Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis , 2015, Arthritis Research & Therapy.

[4]  Sean C. Adams,et al.  Mouse Anesthesia and Analgesia , 2015, Current protocols in mouse biology.

[5]  O. Distler,et al.  Preclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis , 2013, Current opinion in rheumatology.

[6]  Y. Chen,et al.  Action of bleomycin is affected by bleomycin hydrolase but not by caveolin-1. , 2012, International journal of oncology.

[7]  M. Colonna,et al.  Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis , 2012, Annals of the rheumatic diseases.

[8]  Joanne M. Smith,et al.  Health Evaluation of Experimental Laboratory Mice , 2012, Current protocols in mouse biology.

[9]  W. Tourtellotte,et al.  Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. , 2011, Autoimmunity reviews.

[10]  G. Schett,et al.  Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. , 2011, Arthritis & Rheumatism.

[11]  G. Schett,et al.  Animal models of systemic sclerosis: prospects and limitations. , 2010, Arthritis and rheumatism.

[12]  J. Zwerina,et al.  The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. , 2009, Arthritis and rheumatism.

[13]  Oliver Distler,et al.  Dual inhibition of c‐abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  J. Stubbe,et al.  Mechanistic studies on bleomycin-mediated DNA damage: multiple binding modes can result in double-stranded DNA cleavage , 2008, Nucleic acids research.

[15]  John Donovan,et al.  Euthanasia , 2006, Current protocols in immunology.

[16]  S. Kaye,et al.  Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours , 2004, British Journal of Cancer.

[17]  Toshiyuki Yamamoto,et al.  Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains , 2000, Archives of Dermatological Research.

[18]  Toshiyuki Yamamoto,et al.  Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. , 1999, The Journal of investigative dermatology.

[19]  B. Jaffee,et al.  Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. , 1983, Cellular immunology.

[20]  Y. Shima,et al.  Growth Factors , Cytokines , and Cell Cycle Molecules Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma , 2011 .

[21]  M. Fujimoto,et al.  Immunopathology and Infectious Disease CD 19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced Scleroderma , 2010 .

[22]  Oliver Distler,et al.  Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. , 2009, Arthritis and rheumatism.

[23]  Oliver Distler,et al.  Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. , 2007, Arthritis and rheumatism.

[24]  S. L.,et al.  SYSTEMIC SCLEROSIS , 2007 .